2018-01-18T11:56:29-06:00 2016-12-01 263753134 CBIZ TOFIAS 500 BOYLSTON STREET BOSTON MA 02116 990 2016-10-01 364695829 JOSLIN TECHNOLOGIES LLC JOSL 6173092400 ONE JOSLIN PLACE BOSTON MA 02115 MARIA BUCKLEY CLERK 6173092400 2017-12-18 1 CRAIG KLEIN P00734640 6177610600 2017-12-18 207.172.72.163 2017-12-18 09:28:47 ES P 2E51BBD8A5DAF730193DED9248F5B69ECC4FA6A4 2E51BBD8A5DAF730193DED9248F5B69ECC4FA6A4 2016 2021-01-29 14:40:06Z X PETER S AMENTA MD ONE JOSLIN PLACE BOSTON MA 02115 0 0 X WWW.JOSLIN.ORG X LLC 2011 MA JOSLIN TECHNOLOGIES, LLC ("THE ORGANIZATION") WAS AN INTELLECTUAL PROPERTY ACCELERATOR. ITS SOLE FUNCTION WAS TO TAKE SIGNIFICANT INTELLECTUAL PROPERTY OPPORTUNITIES AND DEVELOP THEM ON BEHALF OF ITS SOLE MEMBER, JOSLIN DIABETES CENTER, INC. ("JDC"). X 4 0 0 0 0 0 150000 0 360194 0 0 0 0 0 510194 0 0 0 0 0 0 0 0 0 0 1411802 117508 1411802 117508 -901608 -117508 73254 0 2288408 0 -2215154 0 JOSLIN TECHNOLOGIES, LLC ("THE ORGANIZATION") WAS AN INTELLECTUAL PROPERTY ACCELERATOR. ITS SOLE FUNCTION WAS TO TAKE SIGNIFICANT INTELLECTUAL PROPERTY OPPORTUNITIES AND DEVELOP THEM ON BEHALF OF ITS SOLE MEMBER, JOSLIN DIABETES CENTER, INC. ("JDC"). 0 0 117508 THE ORGANIZATION WAS A COMPANY FOCUSED ON CREATING NOVEL PRODUCTS AND SERVICES IN DIABETES AND OBESITY MANAGEMENT TO ADDRESS THE GROWING NEED FOR BETTER DRUG TREATMENTS, DIAGNOSTICS AND CLINICAL CARE FOR PATIENTS.DIABETES WAS RECOGNIZED AS A GROWING PANDEMIC WITH TWENTY-FIVE (25) MILLION PEOPLE IN THE UNITED STATES SUFFERING FROM THE DISEASE AND ABOUT THREE HUNDRED AND FIFTY (350) MILLION WORLDWIDE. THIS REPRESENTED A SIGNIFICANT MEDICAL RESEARCH MARKET FOR NEW DRUGS, DIAGNOSTIC DEVICES AND INFORMATION TECHNOLOGY APPROACHES FOR IMPROVED CARE AND PATIENT MANAGEMENT. 117508 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 4 0 1 1 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 0 0 0 MA X X BETH CADLE 6173095749 ONE JOSLIN PLACE BOSTON MA 02215 GEORGE KING MD DIRECTOR 1.00 39.00 X 0 343535 50886 NANDAN PADUKONE DIRECTOR 1.00 39.00 X 0 259190 48355 PETER AMENTA CEO/PRESIDENT 1.00 39.00 X X 0 679395 15 ELIOT LURIER CFO/TREASURER 1.00 39.00 X X 0 310530 26132 MARIA BUCKLEY CLERK 1.00 39.00 X 0 300095 32403 JOHN L BROOKS III FORMER CEO/PRESIDENT 0.00 0.00 X 0 501200 24485 0 2393945 182276 0 1 1 0 JOSLIN DIABETES CENTER INC ONE JOSLIN PLACE BOSTON MA 02115 MANAGEMENT SERVICES 113970 1 0 0 0 0 X 117508 117508 117508 117508 0 0 46190 0 0 0 22218 0 0 0 0 0 4846 0 0 0 0 0 0 0 73254 0 40000 0 37499 0 2210909 0 2288408 0 X -2215154 0 -2215154 0 73254 0 X -117508 2332662 X 0 1 X 1 0 X 10000 152000 150000 0 312000 10000 152000 150000 312000 5760 306240 312000 1964878 0.98150 0.98150 X PART II, SHORT YEAR EXPLANATION: JOSLIN TECHNOLOGIES LLC'S FORM 990 FILING FOR THE YEAR ENDING DECEMBER 1, 2016 IS A SHORT YEAR RETURN. THE ENTITY HAS CEASED OPERATIONS AND HAS BEEN LIQUIDATED. 0 X 0 0 0 0 0 113970 0 113970 3538 3538 117508 PART X, LINE 2: JOSLIN, THE CLINIC, AND JOSLIN TECHNOLOGIES HAVE BEEN RECOGNIZED BY THE INTERNAL REVENUE SERVICE (IRS) AS ORGANIZATIONS DESCRIBED IN INTERNAL REVENUE CODE (THE "CODE") SECTION 501(C)(3) AND, THEREFORE, ARE EXEMPT FROM TAXATION ON RELATED INCOME UNDER SECTION 501(A) OF THE CODE. THE IRS HAS ALSO PREVIOUSLY DETERMINED THAT THESE ENTITIES ARE NOT PRIVATE FOUNDATIONS PURSUANT TO SECTION 509(A) OF THE CODE. ACCORDINGLY, NO PROVISION FOR INCOME TAXES HAS BEEN RECORDED IN THE ACCOMPANYING CONSOLIDATED FINANCIAL STATEMENTS. THE CENTER RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED. RECOGNIZED INCOME TAX POSITIONS ARE MEASURED AT THE LARGEST AMOUNT THAT IS GREATER THAN 50% LIKELY OF BEING REALIZED. CHANGES IN RECOGNITION IN MEASUREMENT ARE REFLECTED IN THE PERIOD IN WHICH THE CHANGE IN JUDGMENT OCCURS. THE CENTER DID NOT RECOGNIZE THE EFFECT OF ANY INCOME TAX POSITION IN EITHER 2017 OR 2016. PART XII, LINE 4B - OTHER ADJUSTMENTS: EXPENSES OF DISREGARDED ENTITY 3,538. 1 0 0 0 0 0 0 0 0 GEORGE KING MD DIRECTOR 0 326933 0 9125 0 7477 0 20575 0 30311 0 394421 0 0 NANDAN PADUKONE DIRECTOR 0 257865 0 0 0 1325 0 20575 0 27780 0 307545 0 0 PETER AMENTA CEO/PRESIDENT 0 674114 0 0 0 5281 0 0 0 15 0 679410 0 0 ELIOT LURIER CFO/TREASURER 0 305826 0 0 0 4704 0 2913 0 23219 0 336662 0 0 MARIA BUCKLEY CLERK 0 297677 0 0 0 2418 0 20575 0 11828 0 332498 0 0 JOHN L BROOKS III FORMER CEO/PRESIDENT 0 0 0 0 0 501200 0 0 0 24485 0 525685 0 0 PART I, LINE 4A JOHN L. BROOKS III RECEIVED SEVERANCE PAY IN THE AMOUNT OF $501,200. NET ASSETS 2016-12-01 0 BOOK VALUE AT END OF YEAR 042203836 JOSLIN DIABETES CENTER INC ONE JOSLIN PLACE BOSTON MA 022155306 501(C)(3) 1 1 0 0 1 1 1 1 0 PART I, LINE 2E: EXPLANATION OF INVOLVEMENT: THE FOLLOWING INDIVIDUALS ARE TRUSTEES OR OFFICERS OF JOSLIN DIABETES CENTER INC, THE PARENT OF JOSLIN TECHNOLOGIES LLC: GEORGE KING (TRUSTEE), PETER AMENTA (TRUSTEE AND OFFICER), ELIOT LURIER (OFFICER) AND MARIA BUCKLEY (OFFICER). FORM 990, PART VI, SECTION A, LINE 2 PETER AMENTA, ELIOT LURIER, GEORGE KING, NANDAN PADUKONE AND MARIA BUCKLEY HAVE A BUSINESS RELATIONSHIP. PETER AMENTA SERVES AS CEO AND PRESIDENT OF JOSLIN DIABETES CENTER INC. ELIOT LURIER SERVES AS CFO AND TREASURER OF JOSLIN DIABETES CNETER INC. GEORGE KING SERVES AS CHIEF SCIENTIFIC OFFICER OF JOSLIN DIABETES CENTER INC. NANDAN PADUKONE HEADS THE OFFICE OF COMMERCIALIZATION AND VENTURES OF JOSLIN DIABETES CENTER INC. MARIA BUCKLEY SERVES AS GENERAL COUNSEL OF JOSLIN DIABETES CENTER INC. FORM 990, PART VI, SECTION A, LINE 3 PURSUANT TO A SERVICES AGREEMENT, JOSLIN DIABETES CENTER, INC. WAS SUPERVISING, DIRECTING AND CONTROLLING THE DAY-TO-DAY BUSINESS ACTIVITIES, MANAGEMENT, ADMINISTRATION, AND OPERATION OF JOSLIN TECHNOLOGIES, LLC BUSINESS AND ASSETS. FORM 990, PART VI, SECTION A, LINE 6 JOSLIN TECHNOLOGIES, LLC HAD ONE MEMBER, JOSLIN DIABETES CENTER, INC. ("THE CENTER"). FORM 990, PART VI, SECTION A, LINE 7A JOSLIN TECHNOLOGIES, LLC HAD ONE MEMBER, JOSLIN DIABETES CENTER, INC. ("THE CENTER"), WITH THE POWER TO APPOINT AND REMOVE MEMBERS OF THE GOVERNING BODY. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS REVIEWED BY MEMBERS OF THE FISCAL SERVICES DEPARTMENT FOR COMPLETENESS AND ACCURACY. ONCE REVIEWED AND APPROVED BY FINANCE, A COPY OF THE FORM AS IT WILL BE FILED WITH THE INTERNAL REVENUE SERVICE WAS COMMUNICATED TO THE BOARD OF DIRECTORS PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C THE GENERAL COUNSEL'S OFFICE DISTRIBUTED AN ANNUAL DISCLOSURE FORM TO ALL OFFICERS, TRUSTEES AND EMPLOYEES ANNUALLY. THE INFORMATION DISCLOSED WAS REVIEWED BY THE GENERAL COUNSEL AND, IF A POTENTIAL CONFLICT EXISTED, BY THE COMMITTEE AS DEFINED BELOW. THE DISCLOSURE FORMS OF THE VICE PRESIDENTS WOULD BE REVIEWED BY THE GENERAL COUNSEL AND THE PRESIDENT, THE DISCLOSURE FORM OF THE PRESIDENT WOULD BE REVIEWED BY THE GENERAL COUNSEL AND THE CHAIR OF THE BOARD. IF A POTENTIAL CONFLICT WAS FOUND TO EXIST, THE INDIVIDUAL WOULD REFRAIN FROM ACTIVE PARTICIPATION IN ANY DECISION CONCERNING THE MATTER. FORM 990, PART VI, SECTION C, LINE 19 THE FORM 990 AND THE AUDITED FINANCIAL STATEMENTS ARE AVAILABLE FOR REVIEW AT THE FISCAL SERVICES OFFICE AND THE MASSACHUSETTS ATTORNEY GENERAL'S WEBSITE. THEY ARE ALSO AVAILABLE IN AN ELECTRONIC FORMAT UPON REQUEST. THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND THE WHISTLEBLOWER POLICY ARE AVAILABLE FOR REVIEW AT THE OFFICE OF THE GENERAL COUNSEL OR IN AN ELECTRONIC FORMAT UPON REQUEST. FORM 990, PART VI, SECTION B, LINE 15A & 15B: JOSLIN TECHNOLOGIES, LLC DID NOT DIRECTLY COMPENSATE ITS CEO OR ANY OF ITS OTHER OFFICERS. COMPENSATION FOR THESE INDIVIDUALS WAS SET BY THE JOSLIN DIABETES CENTER ("THE CENTER") FOLLOWING THE PROCEDURES OF THE CENTER AS OUTLINED BELOW: EXECUTIVE COMPENSATION INCLUDES THE CEO AND THE SENIOR LEADERSHIP TEAM. PAY FOR THE CEO IS DETERMINED BY THE BOARD. THE HUMAN RESOURCE DEPARTMENT PROVIDES SURVEY DATA AS REQUESTED. SENIOR LEADERSHIP TEAM PAY IS DETERMINED BY THE CEO WITH SURVEY DATA PROVIDED BY HR. EXECUTIVE COMPENSATION IS REVIEWED ANNUALLY BY THE COMPENSATION COMMITTEE OF THE BOARD. IN ALL CASES, COMPENSATION IS DETERMINED BY INDEPENDENT PERSONS. INDIVIDUALS ARE PROHIBITED FROM ACTIVE PARTICIPATION IN ANY DECISIONS REGARDING THEIR OWN COMPENSATION. FORM 990, PART VI, SECTION B: EXISTENCE OF POLICIES THE CONFLICT OF INTEREST POLICY, WHISTLEBLOWER POLICY AND DOCUMENT RETENTION POLICY FOR THE JOSLIN DIABETES CENTER HAVE BEEN IN EFFECT FOR, AND GOVERNED, JOSLIN TECHNOLOGIES. REGULAR AND CONSISTENT MONITORING AND ENFORCEMENT OF COMPLIANCE WITH THESE POLICIES HAVE BEEN MANAGED BY THE JOSLIN DIABETES CENTER. FORM 990, PART IX, LINE 11G SERVICE AGREEMENTS: PROGRAM SERVICE EXPENSES 117,508. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 117,508. FORM 990, PART XI, LINE 9: DISSOLUTION OF ORGANIZATION 2,332,662. JENESIS BIOSCIENCES LLC ONE JOSLIN PLACE BOSTON MA 02215 MA 0 0 JOSLIN TECHNOLOGIES LLC JOSLIN DIABETES CENTER INC ONE JOSLIN PLACE BOSTON MA 022155306 042203836 DIABETES RESEARCH FACILITY MA 501(C)(3) LINE 7 N/A 0 JOSLIN CLINIC INC ONE JOSLIN PLACE BOSTON MA 022155306 222984590 DIABETES CLINIC MA 501(C)(3) LINE 12A, I N/A 1 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 0